---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Liver-directed therapy"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Liver-directed therapy. Topics: Embolization and cytoreduction for uncontrolled functioning syndromes: ENETS 2023 guidance, Liver-directed options for metastatic insulinoma, Bland hepatic artery embolization for refractory hypoglycemia from insulinoma liver metastases, Chemoembolization and radioembolization for intractable hypoglycemia in metastatic insulinoma, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/liver-directed-therapy"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Liver-directed therapy

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 Liver-directed Therapy

<a id="topic-2.2.2.1.9-1"></a>

### Embolization and cytoreduction for uncontrolled functioning syndromes: ENETS 2023 guidance

> “If the disease is predominantly located in the liver, transarterial bland, chemo- or radioembolisation could be a treatment option in cases of uncontrolled functioning syndrome despite optimal medical therapy [2b, B].”
> “Because of the high morbidity risk associated with this technique in cases of high metastatic load in the liver, the indication must be confirmed in a NET-dedicated multidisciplinary team attended by an interventional radiologist.”
> “Radioembolisation together with chemoembolisation recently proved to be highly effective in controlling hypoglycaemia in a series of seven patients with malignant insulinoma, resulting in an initial clinical success rate of 100% and in an overall clinical success rate of 85%”
> “Cytoreductive surgery can be considered for patients with functioning tumours when ≥70%–90% of visible disease can be debulked.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.9-2"></a>

### Liver-directed options for metastatic insulinoma

> “Also, liver metastases can be resected, or treated by trans-arterial bland or chemo-embolization, radioembolization, radiofrequency ablation, microwave and cryoablation, high-intensity focused ultrasound, laser, brachytherapy, and irreversible electroporation depending on the local availability”
> “However, most aggressive malignant metastatic insulinomas cannot be cured by surgery or ablation procedures alone and require supportive measures, medical antihormonal, and antitumor treatment”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.9-3"></a>

### Bland hepatic artery embolization for refractory hypoglycemia from insulinoma liver metastases

> “Twenty patients (10 women, 10 men; mean age, 56 years; range, 18-84 years) were identified who individually underwent 1 (n = 7), 2 (n = 5), 3 (n = 5), 4 (n = 2), or 5 (n = 1) HAEs, for an overall total of 45 HAEs.”
> “Postprocedural hypoglycemic symptom relief after the first HAE was reported in 100% (n = 20) of patients before discharge or at follow-up.”
> “Post-HAE hypoglycemia recurrence occurred in 60% (n = 12) of patients with a median time to first hypoglycemia recurrence of 2 months (mean, 14 months; range, 0.2-60 months).”
> “After the first HAE, median HFS was 14.5 months, and median OS was 16 months.”
> “IV fluids containing dextrose given preprocedurally in 85% (n = 17) of patients were stopped either immediately postprocedure, on resumption of oral intake, or before discharge, in all patients after the first HAE.”
> “One patient experienced labile postprocedure blood glucose levels requiring intensive care unit admission for intravenous dextrose.”

Source: [Linch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643969/)

<a id="topic-2.2.2.1.9-4"></a>

### Chemoembolization and radioembolization for intractable hypoglycemia in metastatic insulinoma

> “Seven patients were identified (4 male patients).”
> “Technical success rate was 97% (32/33 procedures) with an initial clinical success rate of 100%, defined as absence of recurrent symptomatic hypoglycemia within 1 month after first cycle of LDT and overall clinical success rate of 85%.”
> “Random daytime glucose levels increased from 75.0 (SD, 26) mg/dL to 152.8 (SD, 52.4) mg/dL after LDT.”
> “The mean time to recurrence of intractable hypoglycemia was 21 (SD, 9) months.”

Source: [Habibollahi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32541627/)

<a id="topic-2.2.2.1.9-5"></a>

### Deferral of tumor-directed therapy because of hypoglycemia: manufacturer statement

> “Tumor-directed therapies (e.g., embolization, radio therapy, chemotherapy) deferred because of hypoglycemia”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
